Title:  Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it

United States Patent:  6,426,330

Inventors:  Nyce; Jonathan W. (Greenville, NC); Leonard; Sherry Ann (Greenville, NC)

Assignee:  East Carolina University (Greenville, NC)

Appl. No.:  247755

Filed:  February 9, 1999

Satiety inducing composition comprises Neuropeptide Y analogues which are effective for inducing satiety and for treating diseases and conditions associated with a lacking of, or having lowered, satiety.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The amino acid sequences disclosed herein are presented in the amino to carboxy direction, from left to right. Where the amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented, unless otherwise indicated.

The methods of the present invention are concerned primarily with the treatment of human subjects, but may also be employed for the treatment of other mammalian subjects, such as dogs, cats and cows, for veterinary purposes. Subjects may be those subjects in need of such treatment for any reason for which lowering of blood pressure would be of therapeutic benefit, including but not limited to those subjects afflicted with hypertension or high blood pressure.

The active compounds of the present invention are, in general, NPY analogs that are NPY fragments. The compounds preferably include amino acids 28-35 of NPY, and include a D-Thr amino acid substitution at the Thr³² position. The compounds are preferably at least 8, 9 or 10 amino acids in length, and are preferably not more than 15, 16, 17 or 18 amino acids in-length.

Specific examples of active compounds of the present invention are as follows:

I: D-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH₂(SEQ ID NO:1);

I^Ac : Ac-D-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH₂(SEQ ID NO:2);

IIB: D-Asp-Pro-Lys-Ser-Pro-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH₂ (SEQ ID NO:3);

IIB^Ac : Ac-D-Asp-Pro-Lys-Ser-Pro-Tyr-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Tyr-NH. sub.2 (SEQ ID NO:4);

III: D-Phe(NO₂)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(NO₂)-NH₂ (SEQ ID NO:5);

III^Ac : Ac-D-Phe(NO₂)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(NO₂)-NH. sub.2 (SEQ ID NO:6);

IV: D-Phe(pF)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(pF)-NH₂(SEQ ID NO:7);

IV^Ac : Ac-D-Phe(pF)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(pF)-NH₂ (SEQ ID NO:8);

V: D-Phe(pCl)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(pCl)-NH₂(SEQ ID NO:9);

V^Ac : Ac-D-Phe(pCl)-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phe(pCl)-NH₂ (SEQ ID NO:10);

VI: D-Phg-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phg-NH₂(SEQ ID NO:11);

and

VI^Ac : D-Phg-Ile-Asn-Leu-Ile-D-Thr-Arg-Gln-Arg-D-Phg-NH₂(SEQ ID NO:12).

The terms used herein have their standard meanings. The term "Ac" means acetyl; the term "Phe(NO₂)" refers to phenylalanine substituted by --NO₂on the phenylalanine ring, preferably at the para position, the term "Phe(pCl)" refers to phenylalanine substituted by --Cl on the phenylalanine ring at the para position, and the term "Phe(pF)" refers to phenylalanine substituted by --F on the phenylalanine ring at the para position.

The compounds of the invention may be prepared in accordance with known techniques, such as solid phase-chemistry. See, e.g., U.S. Pat. No. 4,415,558 to Vale et al.

The active compounds disclosed herein may be prepared in the form of their pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b) salts formed from elemental anions such as chlorine, bromine, and iodine, and (c) salts derived from bases, such as ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium, and salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine.

Pharmaceutical compositions for use in the present method of lowering blood pressure include those suitable for inhalation, oral, rectal, topical, (including buccal, sublingual, dermal and intraocular) parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular) and transdermal administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art. The formulations may conveniently be presented in unit dosage form and may be prepared.by any of the methods well known in the art.

The dose of active compound administered will vary according to the route of administration, the manner of formulation, the condition of the subject, and the dose at which adverse pharmacological effects occur. One skilled in the art will take such factors into account when determining dosage. In general, in one preferred embodiment, the dosage will be from 400 or 500 up to about 1000, 2000, or 4000 nM/kg subject body weight.

In the manufacture of a medicament according to the invention (a "formulation"), active agents or the physiologically acceptable salts thereof (the "active compound") are typically admixed with, among other things, an acceptable carrier. The carrier must be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.5% to 99% by weight of the active compound. One or more active compounds may be incorporated in the formulations of the invention (e.g., the formulation may contain one or more additional anti-tubercular agents as noted above), which formulations may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory therapeutic ingredients.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder. Formulations for oral administration may optionally include enteric coatings known in the art to prevent degradation of the formulation in the stomach and provide release of the drug in the small intestine.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The formulations may be presented in unit/dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, e.g., Pharmaceutical Research 3, 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound.

Claim 1 of 73 Claims

That which is claimed is:

1. A satiety inducing composition, comprising

a satiety induced amount of a modified Neuropeptide Y having satiety inducing activity and consisting of a fragment of 8 to 18 amino acids of a Neuropeptide Y, which fragment comprises an amino acid segment selected from the group consisting of amino acids 28 to 35 of a Neuropeptide Y, wherein D-Thr is substituted for Thr at position 32, pharmaceutically acceptable salts thereof, and mixtures thereof; and

a physiologically acceptable carrier.
 

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.